UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 145

Sortiert nach

Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial

PLoS neglected tropical diseases, 2016-10, Vol.10 (10), p.e0005070-e0005070

2016

Link zum Volltext

Verfügbarkeit prüfen

Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa

Nature communications, 2022-06, Vol.13 (1), p.3390-3390, Article 3390

2022

Link zum Volltext

Verfügbarkeit prüfen

Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes

PloS one, 2014-09, Vol.9 (9), p.e106241-e106241

2014

Link zum Volltext

Verfügbarkeit prüfen

Protection against Plasmodium falciparum malaria by PfSPZ Vaccine

JCI insight, 2017-01, Vol.2 (1), p.e89154-e89154

2017

Link zum Volltext

Verfügbarkeit prüfen

Early whole blood transcriptional responses to radiation-attenuated Plasmodium falciparum sporozoite vaccination in malaria naïve and malaria pre-exposed adult volunteers

Malaria journal, 2021-07, Vol.20 (1), p.1-13, Article 308

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of clinical and parasitological data from controlled human malaria infection trials

PloS one, 2012-06, Vol.7 (6), p.e38434-e38434

2012

Link zum Volltext

Verfügbarkeit prüfen

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

Human vaccines, 2010-01, Vol.6 (1), p.97-106

2010

Link zum Volltext

Verfügbarkeit prüfen

Novel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites

Malaria journal, 2019-05, Vol.18 (1), p.186-186, Article 186

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and Clinical Outcome of Experimental Challenge of Human Volunteers with Plasmodium falciparum-Infected Mosquitoes: An Update

The Journal of infectious diseases, 2007-07, Vol.196 (1), p.145-154

2007

Link zum Volltext

Verfügbarkeit prüfen

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

Nature medicine, 2016-06, Vol.22 (6), p.614-623

2016

Link zum Volltext

Verfügbarkeit prüfen

Wearables Detect Malaria Early in a Controlled Human-Infection Study

IEEE transactions on biomedical engineering, 2022-06, Vol.69 (6), p.2119-2129

2022

Link zum Volltext
IEEE_Xplore

Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines

Vaccine, 2015-12, Vol.33 (52), p.7452-7461

2015

Link zum Volltext

Verfügbarkeit prüfen

Taking a bite out of malaria: controlled human malaria infection by needle and syringe

The American journal of tropical medicine and hygiene, 2013-01, Vol.88 (1), p.3-4

Epstein, Judith E

2013

Link zum Volltext

Verfügbarkeit prüfen

Boosting of DNA Vaccine-Elicited Gamma Interferon Responses in Humans by Exposure to Malaria Parasites

Infection and Immunity, 2005-05, Vol.73 (5), p.2863-2872

2005

Link zum Volltext

Verfügbarkeit prüfen

Mannan-Binding Lectin Enhances Susceptibility to Visceral Leishmaniasis

Infection and Immunity, 2001-08, Vol.69 (8), p.5212-5215

2001

Link zum Volltext

Verfügbarkeit prüfen

IMRAS—A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents

PloS one, 2020-06, Vol.15 (6), p.e0233840-e0233840

2020

Link zum Volltext

Verfügbarkeit prüfen

The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review

Current opinion in infectious diseases, 2013-10, Vol.26 (5), p.420-428

2013

Link zum Volltext

Verfügbarkeit prüfen

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity

PloS one, 2013-02, Vol.8 (2), p.e55571

2013

Link zum Volltext

Verfügbarkeit prüfen

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults

PloS one, 2021-09, Vol.16 (9), p.e0256980-e0256980

2021

Link zum Volltext

Verfügbarkeit prüfen

A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines

Vaccine, 2012-08, Vol.30 (36), p.5302-5304

2012

Link zum Volltext

Verfügbarkeit prüfen

Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component

PloS one, 2011-10, Vol.6 (10), p.e25868

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(134)
Mit Volltextzugriff
(125)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial

Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa

Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes

IMRAS-Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS

Protection against Plasmodium falciparum malaria by PfSPZ Vaccine

Early whole blood transcriptional responses to radiation-attenuated Plasmodium falciparum sporozoite vaccination in malaria naïve and malaria pre-exposed adult volunteers

Comparison of clinical and parasitological data from controlled human malaria infection trials

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

Novel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites

Safety and Clinical Outcome of Experimental Challenge of Human Volunteers with Plasmodium falciparum-Infected Mosquitoes: An Update

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

Wearables Detect Malaria Early in a Controlled Human-Infection Study

Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines

Taking a bite out of malaria: controlled human malaria infection by needle and syringe

Boosting of DNA Vaccine-Elicited Gamma Interferon Responses in Humans by Exposure to Malaria Parasites

Multidose Priming and Delayed Boosting Improve Plasmodium falciparum Sporozoite Vaccine Efficacy Against Heterologous P. falciparum Controlled Human Malaria Infection

Mannan-Binding Lectin Enhances Susceptibility to Visceral Leishmaniasis

IMRAS—A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents

The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review

DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity

A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults

Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy

A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines

Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component

Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults

Suchergebnisse filtern